MONDAY, May 12, 2025 (HealthDay News) — The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according to a study published online May 12 in Cancer. Noting that adding bevacizumab to 1L chemotherapy for stage III/IV epithelial ovarian cancer significantly improved progression‐free survival […]
The post Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer first appeared on Physician’s Weekly.
